CD274 and breast cancer: Results from CheckMate 7FL consolidate the benefit of adding an immune checkpoint inhibitor to neoadjuvant CT in this BC subtype and context, and longer follow-up will indicate whether these pCRs translate into greater EFS benefit for all or just for patients with PD-L1+ tumors.